New data show that Tripep’s ChronVac-C® combined with Inovio’s Medpulser® DDS gives an equally good immune response in larger animals as in mice

In the ongoing toxicity studies of Tripep’s ChronVac-C® vaccine, administered using Inovio’s Medpulser® DDS, new analyzes have revealed that the combination induces a humoral immune response in rabbits that is comparable to what Tripep previously have observed in mice. This knowledge is of great importance in the ongoing clinical development of ChronVac-C®, since DNA vaccines have a tendency to not work so well in larger animals when compared to mice. “These results provide encouragement that the combination of ChronVac-C® with the Medpulser® DNA delivery system may work well in humans and indicate that our collaboration with Inovio is progressing very well,” said Tripep’s CEO, Jan Nilsson. “We are pleased to see continuing positive data from this program and Tripep’s ongoing commitment to the development of this DNA vaccine with the goal of initiating a clinical study using Inovio’s Medpulser® DNA delivery system,” stated Avtar Dhillon, MD, Inovio’s president and CEO. For more details on Inovio, please refer to the company’s web site: www.inovio.com. For more information, please contact: Jan Nilsson, CEO, Tripep AB Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63 E-mail: jan.nilsson@tripep.se Anders Vahlne, Head of Research, Tripep AB Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28 E-mail: anders.vahlne@ki.se